This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Biotechs Trading Lower in Q4 on Macro Uncertainty, Tepid Q3
by Zacks Equity Research
After rising 15.4% in the first nine months of the year, the Medical-Biotech /Genetics industry has declined 13.4% so far in the fourth quarter.
Biotech Stock Roundup: Regeneron Delivers Strong Q3 Results, Cellectis Clinical Hold Lifted
by Arpita Dutt
While focus remained on Regeneron's (REGN) Q3 earnings, Dicerna was also in the news related to its collaboration agreement with Boehringer Ingelheim.
Intercept (ICPT) Q3 Loss Narrower Than Expected, Sales Beat
by Zacks Equity Research
Intercept's (ICPT) third-quarter results were encouraging as loss was narrower than expected while Ocaliva registered a sequential increase.
5 Biotech and Pharma Stocks with Key FDA Catalysts this November
by Arpita Dutt
Here is a look at five biotech and pharma stocks including Dynavax (DVAX) that have an important regulatory event lined up this month.
The Zacks Analyst Blog Highlights: JPMorgan Chase, Gilead, ConocoPhillips, General Electric and Walgreens
by Zacks Equity Research
The Zacks Analyst Blog Highlights: JPMorgan Chase, Gilead, ConocoPhillips, General Electric and Walgreens
What's in the Cards for PFE, INCY and ACOR in Q3 Earnings?
by Zacks Equity Research
The third-quarter reporting cycle is witnessing accelerating revenues and positive revisions trend for Q4. Let's see if some of the other leading players like Pfizer, Incyte and Acorda follow suit.
Company News For Oct 30, 2017
by Zacks Equity Research
Companies in the news are: GILD, AXTA, B, AON
Top Research Reports for JPMorgan Chase, Gilead & ConocoPhillips
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase (JPM), Gilead (GILD) and ConocoPhillips (COP).
Gilead (GILD) Down on Weak HCV Sales Despite Q3 Earnings Beat
by Zacks Equity Research
Although Gilead Sciences (GILD) topped estimates in the third quarter, weak HCV sales has dampened investors sentiment.
Gilead (GILD) Q3 Earnings and Revenues Sink
by Benjamin Rains
Gilead Sciences, Inc. (GILD) just released its third-quarter 2017 financial results, posting earnings of $2.06 per share and revenues of $6.51 billion.
Is a Beat in Store for Agenus (AGEN) This Earnings Season?
by Zacks Equity Research
Agenus (AGEN) is expected to report third-quarter 2017 on Oct 26.
Is a Surprise Coming for Gilead Sciences (GILD) This Earnings Season?
by Zacks Equity Research
Gilead Sciences (GILD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP.
Biotech Stock Roundup: Biogen Tops Q3 Earnings, Gilead's CAR T Drug Gets FDA Nod
by Arpita Dutt
Key highlights include Biogen's (BIIB) Q3 results and regulatory news from companies like Gilead and Alexion.
Is a Beat in Store for Alexion (ALXN) This Earnings Season?
by Zacks Equity Research
Alexion's (ALXN) blockbuster drug, Soliris, continues to perform well and the company is scheduled to report third-quarter 2017 results on Oct 26, before the opening bell.
Is Gilead (GILD) Poised for a Beat This Earnings Season?
by Zacks Equity Research
A leader in the hepatitis C virus (HCV) space, Gilead Sciences' (GILD), is expected to beat expectations when it reports third-quarter results on Oct 26, after the market closes.
Gilead Drug Approval Fuels Interest in CAR-T Space: 3 Stocks to Consider
by Arpita Dutt
Will the FDA approval of Novartis and Gilead's (GILD) CAR-T cell therapies fuel more partnership deals and acquisitions in this space?
What's in Store for BioMarin (BMRN) This Earnings Season?
by Zacks Equity Research
BioMarin (BMRN) is likely to see continued momentum in Kuvan sales in Q3. However, slowdown in Federal purchasing orders in Brazil will hurt Naglazyme and Vimizim product revenues.
Gilead (GILD) CAR-T Therapy Yescarta Clinches FDA Approval
by Zacks Equity Research
Gilead (GILD) wins the FDA approval for its CAR-T therapy, Yescarta, for treating refractory aggressive non-Hodgkin lymphoma.
Zacks Market Edge Highlights: Gilead, Biogen, Teva, AbbVie and Aetna
by Zacks Equity Research
Zacks Market Edge Highlights: Gilead, Biogen, Teva, AbbVie and Aetna
Where to Find Value in Healthcare Stocks
by Tracey Ryniec
The Biotech stocks have been on a big run in 2017, but that doesn't mean there aren't some healthcare values still out there.
Zacks Industry Outlook Highlights: Gilead, Teva, Pfizer and Amgen
by Zacks Equity Research
Zacks Industry Outlook Highlights: Gilead, Teva, Pfizer and Amgen
The Zacks Analyst Blog Highlights: NIKE, Cisco Systems, Gilead Sciences, Las Vegas Sands and Aon
by Zacks Equity Research
The Zacks Analyst Blog Highlights: NIKE, Cisco Systems, Gilead Sciences, Las Vegas Sands and Aon
Pharma Industry Outlook - October 2017
by Arpita Dutt
New product sales ramping up, R&D success and innovation, strong results, a higher number of FDA approvals and continued strong performance from key products are some of the factors that could contribute to a sustained recovery in the sector.
Bristol-Myers (BMY), TARGET Extend Partnership for NASH Study
by Zacks Equity Research
Bristol-Myers Squibb (BMY) extended its strategic partnership with TARGET PharmaSolutions, Inc. for NASH study.
Top Stock Reports for NIKE, Cisco Systems & Gilead Sciences
by Zacks Equity Research
Today's Research Daily features new research reports on 16 major stocks, including NIKE (NKE), Cisco Systems (CSCO) and Gilead Sciences (GILD)